Login / Signup

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

Rui-Hua XuLin ShenKe-Ming WangGang WuChun-Mei ShiKe-Feng DingLi-Zhu LinJin-Wan WangJian-Ping XiongChang-Ping WuJin LiYun-Peng LiuDong WangYi BaJue-Ping FengYu-Xian BaiJing-Wang BiLi-Wen MaJian LeiQing YangHao Yu
Published in: Chinese journal of cancer (2017)
Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability. Trial registration This study was registered on ClinicalTrials.gov (NCT01762293) and was orally presented in the 2015 ASCO-Gastrointestinal Symposium.
Keyphrases